TrialGut2022

First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn's disease: an open-label multicentre randomised controlled trial.

Maria M E Jongsma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.